April 29, 2003

Skinvisible Antimicrobial Hand Sanitizer With Proven Persistence Generates Significant Interest From Asian Countries Seeking Protection From SARS Virus

Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website: www.skinvisible.com ) announced that its patent-pending antimicrobial hand sanitizer is receiving strong interest from several Asian countries searching for protective advantages in their fight against the SARS virus. Due to its proven, long-lasting sanitizing capabilities against a wide range of pathogens tested, the formulation may be a significant factor in assisting to reduce transmission through hand contact. The Company is currently in discussions with distributors for the areas Hong Kong, China, Singapore, Malaysia and Taiwan. In addition, negotiations are underway with Canadian and U.S. distributors and product manufacturers.

This increased interest in Skinvisible's antimicrobial hand sanitizer formulation stems from its superior, demonstrated ability to adhere to the skin, forming a protective bond, resisting both wash-off and perspiration while holding the active ingredient Triclosan on the skin for extended periods of time. Independent studies show that the active agent stays on the skin for up to 4 hours per application, maintaining its effectiveness even with frequent hand washings, providing a continuous kill of pathogens tested during that time. Skinvisible's proprietary formulation is alcohol-free, offering distinct advantages over alcohol-based gel sanitizers that typically provide instant protection but offer no long-term persistence, wash off, and require continuous reapplication, sometimes causing adverse reactions.

While Skinvisible's corporate mandate has evolved to focus on marketing its patent-pending polymer-based delivery systems and related technologies to established brand manufacturers, the antimicrobial hand sanitizer was its first finished-product formulation incorporating the innovative delivery system, and was extensively tested by FDA-registered independent laboratories. 'Because we have a proven product which may offer significant potential to protect people and reduce hand contact transmission of this debilitating virus, we are committed wholeheartedly to assist in expeditiously getting product to the marketplace,'says Terry Howlett, the Company's President.

While the fastest solution, currently taking precedence, is to manufacture finished product in response to negotiated agreements, the Company will also continue to produce private label antimicrobial hand sanitizer orders, as well as selling its polymer base as an ingredient either alone or in conjunction with the product formula, and to license its technology to established brand manufacturers.

Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions.

This press release contains 'forward looking'statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-KSB for the year ended December 31, 2002).

For Further Information Contact: T. Howlett - Skinvisible, Inc. - Ph. (702) 433-7154 / Fax (702) 433-7192 / Email: terry@skinvisible.com

Press Release Index

New Press Release Alerts:

If you are interested in receiving corporate and new product development news from Skinvisible, simply enter your email address below.